Alkylating agent; first synthesized in 1959 at the Southern Research Institute. Prepn: Y. F. Shealy et al., J. Org. Chem. 27, 2150 (1962); Hano et al., Gann 59, 207 (1968), C.A. 69, 42527g (1968). Antitumor activity: Shealy et al., Biochem. Pharmacol. 11, 674 (1962); Hano et al., Gann 56, 417 (1965), C.A. 63, 18856g (1965). Mechanism of action studies: Saunders, Schultz, Biochem. Pharmacol. 19, 911 (1970). Metabolism: Skibba et al., ibid. 2043; Mizuno, Humphrey, Cancer Chemother. Rep. Part 1 56, 465 (1972). Electroanalytical behavior: A. J. M. Ordieres et al., Anal. Chim. Acta 202, 141 (1987). Degradation in aqueous soln: B. V. Shetty et al., J. Pharm. Biomed. Anal. 10, 675 (1992). MS study of transition metal coordination: C. G. Hartinger et al., Polyhedron 25, 1971 (2006). Series of articles on history, activity, mechanism of action and clinical studies: Cancer Treat. Rep. 60, 123-214 (1976). Clinical evaluation in pancreatic islet cell cancer: R. K. Ramanathan et al., Ann. Oncol. 12, 1139 (2001). Review of clinical use in metastatic melanoma: A. M. M. Eggermont, J. M. Kirkwood, Eur. J. Cancer 40, 1825-1836 (2004).
Antineoplastic.
Antineoplastic; Alkylating Agents